Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

Journal of Thoracic Oncology

Volumn 10, Issue 3, 2015, Pages 431-437

  Yu, Helena A ^a   Sima, Camelia S ^b   Shen, Ronglai ^b   Kass, Samantha ^a   Gainor, Justin ^c   Shaw, Alice ^c   Hames, Megan ^d   Iams, Wade ^d   Aston, Jonathan ^d   Lovly, Christine M ^d   Horn, Leora ^d   Lydon, Christine ^e   Oxnard, Geoffrey R ^e   Kris, Mark G ^a   Ladanyi, Marc ^b   Riely, Gregory J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Lung cancer, KRAS, Prognostic markers, Adenocarcinoma, Metastatic

Indexed keywords

BEVACIZUMAB; CISPLATIN; PEMETREXED; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CODON; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE K RAS; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMOKING; ADENOCARCINOMA; GENETICS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84937073319     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000432     Document Type: Article

References (47)

1. Slebos RJ, Kibbelaar RE, Dalesio O, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 323 561 565
2. Keohavong P, DeMichele MA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM, Detection of K-ras mutations in lung carcinomas: Relationship to prognosis. Clin Cancer Res 1996 2 411 418
3. Villaruz LC, Socinski MA, Cunningham DE, The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. Cancer 2013 119 2268 2274
4. Tsao MS, Aviel-Ronen S, Ding K, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007 25 5240 5247
5. Schiller JH, Adak S, Feins RH, Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001 19 448 457
6. Graziano SL, Gamble GP, Newman NB, Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999 17 668 675
7. Johnson ML, Sima CS, Chaft J, Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013 119 356 362
8. Mascaux C, Iannino N, Martin B, The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-Analysis. Br J Cancer 2005 92 131 139
9. Mitsudomi T, Steinberg SM, Oie HK, ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991 51 4999 5002
10. Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 363 1693 1703
11. Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 361 947 957
12. Janjigian YY, McDonnell K, Kris MG, Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 2010 116 670 675
13. Paik PK, Johnson ML, D'Angelo SP, Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer 2012 118 5840 5847
14. Riely GJ, Kris MG, Rosenbaum D, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008 14 5731 5734
15. Dogan S, Shen R, Ang DC, Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012 18 6169 6177
16. Jackman DM, Miller VA, Cioffredi LA, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 2009 15 5267 5273
17. Andreyev HJ, Norman AR, Cunningham D, Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001 85 692 696
18. Winder T, Mündlein A, Rhomberg S, Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 2009 21 1283 1287
19. Imamura Y, Morikawa T, Liao X, Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-Type colorectal cancers. Clin Cancer Res 2012 18 4753 4763
20. Al-Mulla F, MacKenzie EM, Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 2001 195 549 556
21. Guerrero S, Casanova I, Farré L, Mazo A, Capellà G, Mangues R, K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000 60 6750 6756
22. Karapetis CS, Khambata-Ford S, Jonker DJ, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008 359 1757 1765
23. De Roock W, Jonker DJ, Di Nicolantonio F, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010 304 1812 1820
24. Mao C, Qiu LX, Liao RY, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-Analysis of 22 studies. Lung Cancer 2010 69 272 278
25. Linardou H, Dahabreh IJ, Kanaloupiti D, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-Targeted agents: A systematic review and meta-Analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008 9 962 972
26. Pirker R, Pereira JR, Szczesna A, FLEX Study Team Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009 373 1525 1531
27. Khambata-Ford S, Harbison CT, Hart LL, Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010 28 918 927
28. Ihle NT, Byers LA, Kim ES, Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. J Natl Cancer Inst 2012 104 228 239
29. Shepherd FA, Domerg C, Hainaut P, Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013 31 2173 2181
30. Rodenhuis S, Boerrigter L, Top B, Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: A prospective study. J Clin Oncol 1997 15 285 291
31. Guan JL, Zhong WZ, An SJ, KRAS mutation in patients with lung cancer: A predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 2013 20 1381 1388
32. Camps C, Jantus-Lewintre E, Cabrera A, The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 2011 72 365 369
33. Kalikaki A, Koutsopoulos A, Hatzidaki D, Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010 69 110 115
34. Pao W, Wang TY, Riely GJ, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005 2 e17
35. Brevet M, Johnson ML, Azzoli CG, Ladanyi M, Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011 73 96 102
36. Matsumoto S, Iwakawa R, Takahashi K, Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007 26 5911 5918
37. Ji H, Ramsey MR, Hayes DN, LKB1 modulates lung cancer differentiation and metastasis. Nature 2007 448 807 810
38. Huang CL, Taki T, Adachi M, Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol 1998 12 553 563
39. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K, K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 1997 75 1125 1130
40. Koivunen JP, Kim J, Lee J, Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008 99 245 252
41. Chen Z, Cheng K, Walton Z, A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012 483 613 617
42. Carretero J, Shimamura T, Rikova K, Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010 17 547 559
43. Mahoney CL, Choudhury B, Davies H, LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009 100 370 375
44. Eberhard DA, Johnson BE, Amler LC, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005 23 5900 5909
45. Massarelli E, Varella-Garcia M, Tang X, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007 13 2890 2896
46. Zhu CQ, da Cunha Santos G, Ding K, National Cancer Institute of Canada Clinical Trials Group Study BR.21 Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 26 4268 4275
47. Douillard JY, Shepherd FA, Hirsh V, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 2010 28 744 752